Kiniksa Pharmaceuticals International, plc
Close on Oct 19, 2026
- Market cap
- $6.63B
- P/E (TTM)
- 81.9
- Dividend yield
- –
Earnings
Next report expected Oct 27, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 28, 2026 | Before market open | $243.60M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 28, 2026 | Before market open | $214.30M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 24, 2026 | Before market open | $202.10M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 28, 2025 | Before market open | $180.90M | $0.23 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 29, 2025 | Before market open | $156.80M | $0.23 | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 29, 2025 | Before market open | $137.80M | $0.11 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 25, 2025 | Before market open | $122.50M | $-0.12 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 29, 2024 | Before market open | $112.20M | $-0.18 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 23, 2024 | Before market open | $108.60M | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 23, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 28, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Jul 28, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| ARCALYST net product revenue | 2026 | $980.00M to $995.00M | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Kiniksa Pharmaceuticals International filed with the SEC
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
Results of operations · EX-99.1 to Form 8-K
Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution
Results of operations · EX-99.1 to Form 8-K
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution
Results of operations · EX-99.1 to Form 8-K
Kiniksa Pharmaceuticals Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution
Results of operations · EX-99.1 to Form 8-K
Announces Trial Design of Planned Phase 2/3 Clinical
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports First Quarter 2025 Financial Results and Recent Portfolio Execution
Results of operations · EX-99.1 to Form 8-K
Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution
Agreement terminated · Results of operations · Exit or restructuring costs · EX-99.1 to Form 8-K
Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
Kiniksa Pharmaceuticals Reports Third Quarter
Results of operations · EX-99.1 to Form 8-K
Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution
Results of operations · EX-99.1 to Form 8-K
Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
Results of operations · EX-99.1 to Form 8-K
Announces Development Indication for Abiprubart
Regulation FD disclosure · EX-99.1 to Form 8-K
The holders of common shares of the Company
Other events · EX-99.1 to Form 8-K
Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution
Results of operations · EX-99.1 to Form 8-K
(rilonacept) 2023 net product revenue grew ~90% year-over-year to $233.1 million (unaudited) –
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Appendix Out - Licensing Agreements
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution
Results of operations · EX-99.1 to Form 8-K
Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution
Results of operations · EX-99.1 to Form 8-K
Kiniksa Pharmaceuticals Reports First Quarter
Results of operations · EX-99.1 to Form 8-K
Kiniksa Pharmaceuticals Reports Fourth Quarter
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Provides Corporate and Portfolio Update
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Material agreement · Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Announces Global License Agreement with Genentech for Vixarelimab
Material agreement · Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Kiniksa Pharmaceuticals Reports First Quarter
Results of operations · EX-99.1 to Form 8-K
Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
Material agreement · Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals and Huadong Medicine Announce Strategic Collaboration
Material agreement · Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Kiniksa Provides Corporate Update and Outlines
Results of operations · EX-99.1 to Form 8-K
Kiniksa Pharmaceuticals Reports Third Quarter
Results of operations · EX-99.1 to Form 8-K